{"id":232548,"date":"2026-03-04T10:09:07","date_gmt":"2026-03-04T16:09:07","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/03\/iga-nephropathy-in-adults"},"modified":"2026-03-04T10:09:07","modified_gmt":"2026-03-04T16:09:07","slug":"iga-nephropathy-in-adults","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/03\/iga-nephropathy-in-adults","title":{"rendered":"IgA Nephropathy in Adults"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/iga-nephropathy-in-adults2.jpg\"><\/a><\/p>\n<p>IgA nephropathy involves deposition of IgA-containing immune complexes in the glomerular mesangium, triggering glomerular inflammation and scarring.<\/p>\n<p>IgA nephropathy is the most common cause of immune-mediated glomerular disease worldwide, with an estimated global incidence between 1.4 and 2.5 per 100 000 persons in the US.<\/p>\n<p>Up to 50% of patients with IgA nephropathy develop kidney failure within 10 years of diagnosis, and life expectancy is estimated to be 6 years shorter for those with IgA nephropathy compared with matched controls.<\/p>\n<p>\ud83d\udcc4 This Review summarizes the pathophysiology, epidemiology, clinical presentation, diagnosis, treatment, and prognosis of primary IgA nephropathy in adults.<\/p>\n<hr>\n<p>This review discusses the pathophysiology, epidemiology, clinical presentation, diagnosis, treatment, and prognosis of primary IgA nephropathy (IgAN) in adults, with a focus on treatment recommendations based on the 2025 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines for IgAN.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>IgA nephropathy involves deposition of IgA-containing immune complexes in the glomerular mesangium, triggering glomerular inflammation and scarring. IgA nephropathy is the most common cause of immune-mediated glomerular disease worldwide, with an estimated global incidence between 1.4 and 2.5 per 100 000 persons in the US. Up to 50% of patients with IgA nephropathy develop kidney [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-232548","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/232548","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=232548"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/232548\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=232548"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=232548"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=232548"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}